{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:42:22Z","timestamp":1776987742807,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Postdoctoral Innovation Program of Shandong Province","award":["SDCX-ZG-202502104"],"award-info":[{"award-number":["SDCX-ZG-202502104"]}]},{"name":"Scientific Research Development Fund Project of Shandong Second Medical University Affiliated Hospital","award":["2024FYQ022"],"award-info":[{"award-number":["2024FYQ022"]}]},{"name":"Weifang Science and Technology Development Plan Project","award":["2024YX014"],"award-info":[{"award-number":["2024YX014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-42815-2","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:53:13Z","timestamp":1773363193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin"],"prefix":"10.1038","volume":"16","author":[{"given":"Zongyang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjiang","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhong","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhilei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"5","key":"42815_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"L van Hoogstraten","year":"2023","unstructured":"van Hoogstraten, L. et al. Global trends in the epidemiology of bladder cancer: Challenges for public health and clinical practice. Nat. Rev. Clin. Oncol. 20 (5), 287\u2013304 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"42815_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","volume":"5","author":"N Lobo","year":"2022","unstructured":"Lobo, N. et al. Epidemiology, screening, and prevention of bladder cancer. Eur. Urol. Oncol. 5 (6), 628\u2013639 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"42815_CR3","doi-asserted-by":"crossref","unstructured":"Im, S. W. et al. Genomic landscape of young-onset bladder cancer and its prognostic implications on adult bladder cancer. Cancers (Basel) 12(2), 307 (2020).","DOI":"10.3390\/cancers12020307"},{"issue":"1","key":"42815_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semradonc.2022.10.005","volume":"33","author":"B Venkatesulu","year":"2023","unstructured":"Venkatesulu, B. et al. Multidisciplinary management and radiotherapy recommendations for clinically and pathologically node-positive bladder cancer. Semin Radiat. Oncol. 33 (1), 35\u201350 (2023).","journal-title":"Semin Radiat. Oncol."},{"issue":"2","key":"42815_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.4111\/icu.2019.60.2.64","volume":"60","author":"DK Kim","year":"2019","unstructured":"Kim, D. K., Lee, J. Y., Jung, J. H., Hah, Y. S. & Cho, K. S. Role of adjuvant cisplatin-based chemotherapy following radical cystectomy in locally advanced muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized trials. Investig. Clin. Urol. 60 (2), 64\u201374 (2019).","journal-title":"Investig. Clin. Urol."},{"key":"42815_CR6","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.eururo.2025.02.019","volume":"87","author":"AG van der Heijden","year":"2025","unstructured":"van der Heijden, A. G. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2025 guidelines. Eur. Urol. 87, 582\u2013600 (2025).","journal-title":"Eur. Urol."},{"key":"42815_CR7","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1007\/s12094-025-04045-2","volume":"27","author":"P Javier","year":"2025","unstructured":"Javier, P. et al. SEOM-SOGUG clinical guideline for urothelial cancer (2025). Clin. Transl Oncol. 27, 4142\u20134159 (2025).","journal-title":"Clin. Transl Oncol."},{"key":"42815_CR8","doi-asserted-by":"publisher","first-page":"1591191","DOI":"10.3389\/fimmu.2025.1591191","volume":"16","author":"F Zhang","year":"2025","unstructured":"Zhang, F. & Li, S. Antibody-drug conjugates as game changers in bladder cancer: Current progress and future directions. Front. Immunol. 16, 1591191 (2025).","journal-title":"Front. Immunol."},{"issue":"15","key":"42815_CR9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.1016\/j.ejca.2015.07.028","volume":"51","author":"R Marcos-Gragera","year":"2015","unstructured":"Marcos-Gragera, R. et al. Urinary tract cancer survival in Europe 1999\u20132007: Results of the population-based study EUROCARE-5. Eur. J. Cancer. 51 (15), 2217\u20132230 (2015).","journal-title":"Eur. J. Cancer"},{"key":"42815_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.matbio.2017.11.014","volume":"71\u201372","author":"DB Rifkin","year":"2018","unstructured":"Rifkin, D. B., Rifkin, W. J. & Zilberberg, L. LTBPs in biology and medicine: LTBP diseases. Matrix Biol. 71\u201372, 90\u201399 (2018).","journal-title":"Matrix Biol."},{"issue":"844","key":"42815_CR11","doi-asserted-by":"publisher","first-page":"eadn6052","DOI":"10.1126\/scisignal.adn6052","volume":"17","author":"JW Jackson","year":"2024","unstructured":"Jackson, J. W. et al. An antibody that inhibits TGF-\u03b21 release from latent extracellular matrix complexes attenuates the progression of renal fibrosis. Sci. Signal. 17 (844), eadn6052 (2024).","journal-title":"Sci. Signal."},{"issue":"1","key":"42815_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/dvdy.331","volume":"251","author":"D Rifkin","year":"2022","unstructured":"Rifkin, D. et al. The role of LTBPs in TGF beta signaling. Dev. Dyn. 251 (1), 95\u2013104 (2022).","journal-title":"Dev. Dyn."},{"issue":"3","key":"42815_CR13","doi-asserted-by":"publisher","first-page":"102000","DOI":"10.1016\/j.xcrm.2025.102000","volume":"6","author":"S Yang","year":"2025","unstructured":"Yang, S. et al. LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1\/LTBP1\/TGF-\u03b2 axis. Cell. Rep. Med. 6 (3), 102000 (2025).","journal-title":"Cell. Rep. Med."},{"issue":"1","key":"42815_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.molcel.2019.09.018","volume":"77","author":"Q Zhao","year":"2020","unstructured":"Zhao, Q. et al. PTPS facilitates compartmentalized LTBP1 S-nitrosylation and promotes tumor growth under hypoxia. Mol. Cell. 77 (1), 95\u2013107e5 (2020).","journal-title":"Mol. Cell."},{"key":"42815_CR15","doi-asserted-by":"crossref","unstructured":"Morini, M. et al. Plasma-derived exosome proteins as novel diagnostic and prognostic biomarkers in neuroblastoma patients. Cells 12(21). (2023).","DOI":"10.3390\/cells12212516"},{"issue":"1","key":"42815_CR16","first-page":"19","volume":"9","author":"X Lin","year":"2022","unstructured":"Lin, X. et al. N(6)-methyladenosine modification of CENPK mRNA by ZC3H13 promotes cervical cancer stemness and chemoresistance. Mil Med. Res. 9 (1), 19 (2022).","journal-title":"Mil Med. Res."},{"issue":"1","key":"42815_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41419-022-04510-8","volume":"13","author":"W Tian","year":"2022","unstructured":"Tian, W. et al. Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell. Death Dis. 13 (1), 64 (2022).","journal-title":"Cell. Death Dis."},{"issue":"1","key":"42815_CR18","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13287-022-02859-3","volume":"13","author":"Y Zhang","year":"2022","unstructured":"Zhang, Y. et al. Epiregulin increases stemness-associated genes expression and promotes chemoresistance of non-small cell lung cancer via ERK signaling. Stem Cell. Res. Ther. 13 (1), 197 (2022).","journal-title":"Stem Cell. Res. Ther."},{"issue":"12","key":"42815_CR19","doi-asserted-by":"publisher","first-page":"4392","DOI":"10.3390\/ijms21124392","volume":"21","author":"J Hrab\u011bta","year":"2020","unstructured":"Hrab\u011bta, J. et al. Drug sequestration in lysosomes as one of the mechanisms of chemoresistance of cancer cells and the possibilities of its inhibition. Int. J. Mol. Sci. 21 (12), 4392 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"26","key":"42815_CR20","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.3748\/wjg.v28.i26.3027","volume":"28","author":"MB Novoa D\u00edaz","year":"2022","unstructured":"Novoa D\u00edaz, M. B., Mart\u00edn, M. J. & Gentili, C. Tumor microenvironment involvement in colorectal cancer progression via Wnt\/\u03b2-catenin pathway: Providing understanding of the complex mechanisms of chemoresistance. World J. Gastroenterol. 28 (26), 3027\u20133046 (2022).","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"42815_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s11658-022-00348-2","volume":"27","author":"M Vaghari-Tabari","year":"2022","unstructured":"Vaghari-Tabari, M. et al. CRISPR\/Cas9 gene editing: A new approach for overcoming drug resistance in cancer. Cell. Mol. Biol. Lett. 27 (1), 49 (2022).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"42815_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.matbio.2022.08.001","volume":"112","author":"K Singh","year":"2022","unstructured":"Singh, K., Sachan, N., Ene, T., Dabovic, B. & Rifkin, D. Latent transforming growth factor \u03b2 binding protein 3 controls adipogenesis. Matrix Biol. 112, 155\u2013170 (2022).","journal-title":"Matrix Biol."},{"issue":"2","key":"42815_CR23","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1021\/acs.jproteome.3c00629","volume":"23","author":"D Wenk","year":"2024","unstructured":"Wenk, D. et al. Targeted mass spectrometry of longitudinal patient sera reveals LTBP1 as a potential surveillance biomarker for high-grade serous ovarian carcinoma. J. Proteome Res. 23 (2), 749\u2013759 (2024).","journal-title":"J. Proteome Res."},{"issue":"7","key":"42815_CR24","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.7150\/ijms.96274","volume":"21","author":"J Liao","year":"2024","unstructured":"Liao, J. et al. Cross-talk between the TGF-\u03b2 and cell adhesion signaling pathways in cancer. Int. J. Med. Sci. 21 (7), 1307\u20131320 (2024).","journal-title":"Int. J. Med. Sci."},{"issue":"8","key":"42815_CR25","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/stmcls\/sxae032","volume":"42","author":"Q Zhang","year":"2024","unstructured":"Zhang, Q. et al. Tibetan mesenchymal stem cell-derived exosomes alleviate pulmonary vascular remodeling in hypoxic pulmonary hypertension rats. Stem Cells. 42 (8), 720\u2013735 (2024).","journal-title":"Stem Cells"},{"key":"42815_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.semcdb.2020.12.012","volume":"114","author":"E Spina","year":"2021","unstructured":"Spina, E. & Cowin, P. Embryonic mammary gland development. Semin Cell. Dev. Biol. 114, 83\u201392 (2021).","journal-title":"Semin Cell. Dev. Biol."},{"issue":"1","key":"42815_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12967-020-02310-2","volume":"18","author":"R Cai","year":"2020","unstructured":"Cai, R. et al. LTBP1 promotes esophageal squamous cell carcinoma progression through epithelial-mesenchymal transition and cancer-associated fibroblasts transformation. J. Transl Med. 18 (1), 139 (2020).","journal-title":"J. Transl Med."},{"issue":"1","key":"42815_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10142-024-01311-4","volume":"24","author":"X Jiang","year":"2024","unstructured":"Jiang, X. et al. A prognostic marker LTBP1 is associated with epithelial mesenchymal transition and can promote the progression of gastric cancer. Funct. Integr. Genomics. 24 (1), 30 (2024).","journal-title":"Funct. Integr. Genomics"},{"issue":"Pt 2","key":"42815_CR29","first-page":"136","volume":"86","author":"JH Lee","year":"2022","unstructured":"Lee, J. H. & Massagu\u00e9, J. TGF-\u03b2 in developmental and fibrogenic EMTs. Semin Cancer Biol. 86 (Pt 2), 136\u2013145 (2022).","journal-title":"Semin Cancer Biol."},{"key":"42815_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2023.10.004","volume":"97","author":"X Wang","year":"2023","unstructured":"Wang, X., Eichhorn, P. & Thiery, J. P. TGF-\u03b2, EMT, and resistance to anti-cancer treatment. Semin Cancer Biol. 97, 1\u201311 (2023).","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"42815_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","volume":"21","author":"D Peng","year":"2022","unstructured":"Peng, D., Fu, M., Wang, M., Wei, Y. & Wei, X. Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy. Mol. Cancer. 21 (1), 104 (2022).","journal-title":"Mol. Cancer"},{"key":"42815_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2024.04.001","volume":"101","author":"YE Zhang","year":"2024","unstructured":"Zhang, Y. E. & Stuelten, C. H. Alternative splicing in EMT and TGF-\u03b2 signaling during cancer progression. Semin Cancer Biol. 101, 1\u201311 (2024).","journal-title":"Semin Cancer Biol."},{"issue":"6","key":"42815_CR33","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41568-023-00581-7","volume":"23","author":"A Dart","year":"2023","unstructured":"Dart, A. EMT in chemoresistance. Nat. Rev. Cancer. 23 (6), 349 (2023).","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"42815_CR34","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1002\/jcp.31048","volume":"238","author":"F Farooq","year":"2023","unstructured":"Farooq, F., Amin, A., Wani, U. M., Lone, A. & Qadri, R. A. Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance. J. Cell. Physiol. 238 (8), 1651\u20131669 (2023).","journal-title":"J. Cell. Physiol."},{"key":"42815_CR35","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-030-40146-7_4","volume":"1245","author":"P Qiao","year":"2020","unstructured":"Qiao, P. & Lu, Z. R. Fibronectin in the tumor microenvironment. Adv. Exp. Med. Biol. 1245, 85\u201396 (2020).","journal-title":"Adv. Exp. Med. Biol."},{"key":"42815_CR36","doi-asserted-by":"publisher","first-page":"107753","DOI":"10.1016\/j.pharmthera.2020.107753","volume":"221","author":"Y Xiao","year":"2021","unstructured":"Xiao, Y. & Yu, D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol. Ther. 221, 107753 (2021).","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"42815_CR37","first-page":"736","volume":"12","author":"E Agosti","year":"2023","unstructured":"Agosti, E. et al. Tumor microenvironment and glioblastoma cell interplay as promoters of therapeutic resistance. Biology (Basel). 12 (5), 736 (2023).","journal-title":"Biology (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42815-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42815-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42815-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T23:16:28Z","timestamp":1776986188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-42815-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["42815"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-42815-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Research Ethics Committee of The First Affiliated Hospital of Shandong Second Medical University (KYLL20240530-1) and complied with the rules of the Declaration of Helsinki principles. The animal experiments were approved by the Laboratory Animal Center of Shandong Second Medical University (2023SDL338). All animal procedures were conducted according with international guidelines and the Basel Declaration. We complied with the ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"13328"}}